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We investigated whether antibodies against intracellular tumor-
associated antigens support tumor-specific immunity when 
administered together with a treatment that destroys the tumor. We 
propose that released antigens form immune complexes with the 
antibodies, which are then efficiently taken up by dendritic cells. We 
cloned the first human monoclonal antibodies against the Cancer/
Testis (CT) antigen, NY-ESO-1. We tested whether the monoclonal 
anti-NY-ESO-1 antibody (12D7) facilitates cross-presentation of a 
NY-ESO-1-derived epitope by dendritic cells to human CD8+ T cells, 
and whether this results in the maturation of dendritic cells in vitro. 
We investigated the efficacy of 12D7 in combination with 
chemotherapy using BALB/c mice bearing syngeneic CT26 tumors 
that express intracellular NY-ESO-1. Human dendritic cells that were 
incubated with NY-ESO-1:12D7 immune complexes efficiently 
stimulated NY-ESO-1157-165/HLA-A2-specific human CD8+ T cells to 
produce interferon-, whereas NY-ESO-1 alone did not. 
Furthermore, the incubation of dendritic cells with NY-ESO-1:12D7 
immune complexes resulted in the maturation of dendritic cells. 
Treatment of BALB/c mice that bear CT26/NY-ESO-1 tumors with 5-
fluorouracil (5-FU) plus 12D7 was significantly more effective than 
chemotherapy alone. We propose systemic injection of monoclonal 
antibodies (mAbs) against tumor-associated antigens plus a 
treatment that promotes the local release of those antigens resulting 
in immune complex formation as a novel therapeutic modality for 
cancer.
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Introduction
Cancer/Testis (CT) antigens form an extended family of 
proteins that are frequently expressed in a large variety of 
malignancies but are absent from healthy tissue, except for the 
testis and placenta. Cancer patients often develop spontaneous 
immune responses toward CT antigens, which illustrate their 
immunogenicity (1-3). Their apparent immunogenicity and 
unique expression pattern make CT antigens attractive targets 
for immunotherapy, and a number of clinical trials in which 
cancer patients were immunized with CT antigens in different 
forms have been completed, some of which show objective 
clinical responses (4-12).
Dendritic cell (DC) maturation is a key prerequisite for the 
activation of T cells, and moreover, antigen presentation by 
steady-state DCs results in peripheral tolerance induction, a 
process that is considered crucial for the protection against 
autoimmunity (13, 14). DC maturation usually is induced by 
infection or inflammation—or by adjuvants for that matter—
and can be a local event. Insufficient maturation of tumor-
associated DCs may be one of multiple reasons for the 
compromised response of tumor-infiltrating T cells compared 
to peripheral T cells (15, 16). Cross-presentation of sufficient 
amounts of tumor-derived antigens may be another limiting 
factor, especially because the number of tumor-associated DCs 
often is low and cross-presentation is inefficient (17, 18). 
Therefore, we developed a novel immunotherapeutic approach 
that combines enhanced cross-presentation of epitopes derived 
from intracellular proteins with concomitant DC maturation. 
We hypothesized that administration of monoclonal antibodies 
(mAbs) against CT antigens together with a therapy that releases 
these usually intracellular antigens may support the local 
formation of immune complexes, which are efficiently taken up 
by DCs (19, 20) resulting in increased presentation of CT 
antigen-derived epitopes to CD8+ T cells. Because there is 
evidence that the uptake of immune complexes by DCs through 
the activating receptor for IgG (FcRIIA) results in DC 
maturation (21), the use of mAbs against CT antigens may serve 
both purposes: DC activation and enhanced cross-presentation.
The fact that NY-ESO-1 is one of the best-characterized and 
most immunogenic CT antigens known to date (22, 23) and is 
frequently expressed by tumors of different origin (6, 24) 
prompted us to clone human-derived mAbs against NY-ESO-1 
from patients who had high serum levels of NY-ESO-1-specific 
IgG and, thus, presumably a high frequency of NY-ESO-1-
specific B cells. The obvious advantage of cloning a therapeutic 
antibody from humans is that adverse side effects of such an 
antibody are very unlikely and that it therefore can relatively be 
quickly tested in clinical trials. We report here the generation of 
the first human-derived IgG1 mAbs against NY-ESO-1 and the 
selection of a lead development candidate (12D7). We show that 
12D7 facilitates cross-presentation of a NY-ESO-1-derived 
epitope to CD8+ T cells, that 12D7:NY-ESO-1 immune 
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complexes induce the maturation of human monocyte-derived 
DCs in vitro, and that 12D7 significantly enhances the 
therapeutic efficacy of chemotherapy using a preclinical 
syngeneic mouse model.
Table 1 
Binding of human monoclonal anti-NY-ESO-1 antibodies to NY-
ESO-1. Comparison of EC50 and equilibrium affinity constants for 
the binding between NY-ESO-1 and different anti-NY-ESO-1 anti-
bodies. 
Results
Cloning of human-derived monoclonal antibodies from cancer 
patients
We cloned eight different NY-ESO-1-specific human-derived 
monoclonal antibodies (HD mAbs) from a melanoma patient, 
of which the following five were selected for further analysis 
based on their affinity to the target: 1D4, 12D7, 15B12, 30D6, 
and 31E4. All HD mAbs were of IgG1 isotype.
In vitro characterization of HD mAbs
To compare the binding properties of five different anti-NY-
ESO-1 HD mAbs to recombinant NY-ESO-1 protein, we 
determined the half-maximal effective concentration (EC50) 
using a protein ELISA. All antibodies bound recombinant NY-
ESO-1 produced in bacteria in the low pM range. Actual 
binding constants to recombinant NY-ESO-1 produced in 
bacteria and in eukaryotic cells were determined by surface 
plasmon resonance (Biacore Systems) (Table 1).
To determine the epitopes recognized by the different mAbs, 
we used a set of overlapping peptides spanning the complete 
NY-ESO-1 protein as coating antigen in ELISA. As shown in 
Figure 1A, 12D7 binds to a peptide representing the amino acids 
11 to 30 from the NY-ESO-1 protein, but not to the two adjacent 
peptides that span amino acids 1-20 or 21-40. This suggests that 
the epitope recognized by 12D7 lies at the junction of these two 
peptides around amino acid 20 of NY-ESO-1. Figure 1B 
summarizes the epitope-specificity of all five anti-NY-ESO-1 
antibodies. In addition, all antibodies were tested for binding to 
endogenous NY-ESO-1 from the human melanoma cell line SK-
MEL-37 by immunoprecipitation. All antibodies precipitate NY-
ESO-1 from a cell lysate of an NY-ESO-1+ cell line (SK-MEL-
37) (Figure 1C). Because 12D7 had the highest affinity for 
eukaryotic NY-ESO-1, we performed further experiments with 
this mAb.
12D7 facilitates cross-presentation of NY-ESO-1 by DCs and induces 
concomitant DC maturation
To test whether 12D7 facilitates the cross-presentation of NY-
ESO-1-derived epitopes in vitro, we generated monocyte-
derived, HLA-A*0201+ DCs and fed them with 12D7:NY-ESO-
1 immune complexes, NY-ESO-1, or 12D7. DCs were 
subsequently incubated with cloned NY-ESO-1157-165/HLA-
A*0201-specific CD8+ T cells, and the percentage of T cells that 
produced IFN- was used as readout for antigen recognition. 
Mature DCs fed with NY-ESO-1 protein induced IFN-
production in a low but discernible percentage of T cells 
(Figure 2A, black bars), which did not occur when DCs were not 
matured (Figure 2A, white bars). DCs fed with 12D7:NY-ESO-1 
immune complexes induced the production of IFN- in a much 
Figure 1
Epitope mapping of anti-NY-ESO-1 human monoclonal antibodies. (A) Representative peptide ELISA for antibody 12D7, where P1-P17 represent overlapping NY-
ESO-1 peptides. (B) Overview of the specificities of different NY-ESO-1 specific human-derived mAbs. (C) Immunoprecipitation of NY-ESO-1 from a cell lysate of a 
NY-ESO-1+ cell line SK-MEL-37 or a NY-ESO-1- cell line A549 by human anti-NY-ESO-1 mAbs.
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Figure 2
Human monoclonal anti-NY-ESO-1 antibody (12D7) facilitates cross-presentation of a NY-ESO-1-derived, HLA-A2-restriced epitope (NY-ESO-1157-165). (A) 
HLA-A2+, monocyte-derived DCs were incubated with 20 μg NY-ESO-1 protein, 200 μg human monoclonal anti-NY-ESO-1 antibody (12D7), with immune complexes 
(12D7:NY-ESO-1) or with media for 3 h, were washed and cultured for 36 h with (black bars) or without (white bars) 25 ng/mL TNF- + 1 μg/mL sCD40L (maturation 
cocktail). 6 x 104 cloned, NY-ESO-1157-165 /HLA-A2-specific CD8+ T cells were added to 10
5 DCs in the presence of 10 μg/mL Brefeldin A, followed by a 5 h incubation 
and subsequent surface staining for CD8 and intracellular staining for IFN-. 10-6 M peptide was added to DCs as positive control. All cultures were performed in tripli-
cate. (B) HLA-A2+, monocyte-derived DCs were incubated with 20 μg NY-ESO-1 protein, 200 μg human monoclonal anti-NY-ESO-1 antibody (12D7), with lysate of 
107 NY-ESO-1+ SK-MEL-37 cells (lysate), with immune complexes (NY-ESO-1:12D7 or lysate:12D7), or with media (0) for 3 h, were washed and cultured for 36 h with 
25 ng/mL TNF-+ 1 μg/mL sCD40L (maturation cocktail). 6 x 104 cloned, NY-ESO-1157-165 /HLA-A2-specific CD8+ T cells were added to 105 DCs in the presence of 
10 μg/mL Brefeldin A, followed by a 5 h incubation and subsequent surface staining for CD8 and intracellular staining for IFN-. All cultures were performed at least in 
duplicate.
higher percentage of T cells and, importantly, also did so when 
DCs that were not deliberately matured were used (Figure 2A, 
compare black and white bars). None of the negative controls—
DCs fed with 12D7, mock immune complexes, or medium—
induced IFN- production (Figure 2A and data not shown). To 
exclude that our observations are a peculiarity of recombinant 
NY-ESO-1, we incubated 12D7 with a cell lysate of SK-MEL-37 
cells, which naturally express NY-ESO-1, and subsequently fed 
this mixture to DCs. DCs fed with the 12D7:lysate or with 
12D7:NY-ESO-1 presented NY-ESO-1-derived epitopes 
approximately equally well (Figure 2B).
Because presentation of 12D7:NY-ESO-1 immune complexes 
seemed not to require deliberate DC maturation, we addressed 
whether the uptake of immune complexes, but not the uptake of 
uncomplexed protein, induced DC maturation in vitro. We 
therefore compared the expression of three surface molecules 
that are upregulated on mature DCs (CD83, CD86, and MHC 
class II) after incubation with media, 12D7, NY-ESO-1, or with 
12D7:NY-ESO-1 immune complexes in the absence of 
maturation cocktail. We found that only immune complexes 
induced an upregulation of CD86, CD83, and MHC II 
(Figure 3A; left, middle, and right panels, respectively). We then 
compared the expression of CD83, CD86, and MHC II on DCs 
that were incubated with the maturation cocktail, with immune 
complexes, or with both, in order to determine the relative 
potency of immune complexes with respect to DC maturation. 
We found that immune complexes were almost as potent in 
inducing DC maturation as the classical maturation cocktail 
(sCD40L plus TNF-) (Figure 3B). A combination of immune 
complexes plus maturation cocktail resulted in the most 
pronounced upregulation of CD86 and CD83 (Figure 3B; left 
and middle panels, respectively), whereas MHC II was not 
further upregulated compared to any of the two treatments 
alone (Figure 3B, right panels).
12D7 increases the therapeutic efficacy of chemotherapy in mice 
with NY-ESO-1+ tumors
To test the therapeutic efficacy of 12D7 in vivo, we injected 106
syngeneic, NY-ESO-1-transfected CT26 tumor cells s.c. in 
BALB/c mice. To induce release of intracellular NY-ESO-1, mice 
were treated with 75 mg/kg 5-FU when tumors reached a size of 
approximately 25 mm2, which was typically around 2 weeks after 
injection of tumor cells. The treatment with 5-FU was repeated 
one week later and, in some groups, was combined with 100 μg 
12D7 given systemically 2 d after each 5-FU injection. As can be 
seen from the growth curves, 5-FU has the expected therapeutic 
effect. Importantly, this was enhanced by 12D7 (Figure 4A). 
Treatment with 12D7 alone had no effect, presumably because 
the amount of spontaneously released antigen is not sufficient in 
this particular model. A compilation of end-point tumor sizes 
from 4 independent experiments shows a highly significant 
difference between mice treated with 5-FU plus 12D7, and mice 
treated with 5-FU alone (Figure 4B).
To investigate whether treatment with 5-FU plus 12D7 
supported tumor-specific immunity, we injected mice with 
Brefeldin A 4 h before euthanasia, followed by staining for 
CD45.2, CD8, and intracellular IFN-. This way of analysis 
shows which cells actually are making IFN- in vivo and not 
which cells potentially can do this upon in vitro restimulation 
with peptide. This method obviously does not allow 
discrimination between single peptide specificities, but it is of 
higher biological relevance (25) particularly because we 
envisaged that DC activation, which we have shown to occur 
upon cross-presentation (Figure 3), may also support the 
presentation of other epitopes besides those derived from NY-
ESO-1. Treatment with 5-FU plus 12D7 supported CD8+ and
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Figure 3
Immune complexes induce maturation of monocyte-derived DCs in vitro. (A) CD14-derived DCs were incubated with media, 200 μg NY-ESO-1, 20 μg 12D7 or pre-
formed immune complexes of 20 μg 12D7 + 200 μg NY-ESO-1, and were analyzed 36 h later for surface expression of CD86, CD83, or MHC II. (B) CD14-derived DCs 
were incubated with preformed immune complexes of 20 μg 12D7 + 200 μg NY-ESO-1, maturation cocktail (sCD40L + TNF-) or with preformed immune complexes 
plus maturation cocktail, and were analyzed 36 h later for surface expression of CD86, CD83, or MHC II.
effector function in the tumor (Figure 4C). Treatment with 5-
FU (Figure 4C) or 12D7 (data not shown) did not have this 
effect.
Discussion
We hypothesized that antibodies against intracellular, tumor-
associated antigens support tumor-specific immunity when 
used in combination with a therapy that induces cell death such 
as chemo- or radiotherapy. We envisaged that such antibodies 
form immune complexes with the released tumor antigens. 
These immune complexes are subsequently taken up with 
higher efficiency compared to protein (fragments) by DCs (26), 
which then cross-present relevant epitopes to local CD8+, 
tumor-specific T cells. This presumed sequence of events may 
be of particular interest as evidence is accumulating that both 
chemo- and radiotherapy support tumor-specific immunity 
(27), and we therefore reasoned that additional stimulation of 
tumor-specific immunity could further improve the efficacy of 
these standard therapies.
For this purpose, we have cloned the first fully human mAbs to 
NY-ESO-1 using Epstein-Barr virus (EBV)-transformed B cells 
from a melanoma patient and subjected those to preclinical 
experiments to obtain proof of principle. We found that 12D7, a 
fully human IgG1 mAb specific for the immunogenic CT 
antigen NY-ESO-1, supported cross-presentation of NY-ESO-1 
in vitro resulting in an approximate 15-fold increase of the 
number of responding CD8+ T cells. Of the other four NY-ESO-
1-specific mAbs we generated here, 1D4 and 30D6 improved 
cross-presentation of NY-ESO-1 (data not shown), whereas 
15B12 and 31E4 seemed not effective (data not shown). This 
difference may be explained by the difference in affinity, as 
15B12 did not show binding to NY-ESO-1 by Biacore—although 
it did bind weakly to NY-ESO-1 in ELISA—and 31E4 had at 
least a 1-log lower affinity than 12D7, 1D4, and 30D6. At 
present, we have no reason to think that the epitope recognized 
by the mAb impacts on its ability to support cross-presentation. 
Our observation that 12D7:NY-ESO-1 immune complexes are 
considerably less efficient than peptide-loaded DCs in 
stimulating IFN- production illustrates that cross-presentation 
is a rather inefficient process, but underscores the therapeutic 
potential of antibodies against tumor-associated antigens.
It is well accepted now that activation of T cells in vivo
crucially depends on antigen presentation by mature or 
activated DCs (14, 28). Many cues, including inflammation and 
infection but also endogenous signals, can induce DC 
maturation (29), and the lack of such signals in the tumor 
environment may be one reason why tumor-infiltrating T cells 
often have compromised functions (16, 30). Because the uptake 
of immune complexes was shown to result in DC maturation 
(19), we specifically addressed this issue here. We found that the 
in vitro uptake of immune complexes resulted in DC maturation 
that was comparable to sCD40L plus TNF-, which is a classical 
maturation cocktail. Therefore, the use of mAbs against CT 
antigens may serve both purposes: DC activation and enhanced 
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Figure 4
A human, monoclonal anti-NY-ESO-1 antibody (12D7) increases the therapeutic efficacy of 5-FU chemotherapy in mice bearing NY-ESO-1+ syngeneic tumors. 
Female BALB/c mice were injected s.c. with 106 CT26/NY-ESO-1+ cells and treatment was started when tumors reached a surface of approximately 25 mm2 (~ d13-15). 
(A) Mice received 75 mg/kg 5-FU i.p. at days 15 and 22 and/or 100 μg 12D7 i.p. on days 17 and 24. The results are shown as mean±SD. A representative experiment of 4 
experiments is shown. (B) Compilation of 4 independent experiments, each symbol represents the tumor surface of an individual mouse at the end of the experiment (d 
29). (C) Mice were injected i.p. 1 week after the last injection with 12D7 (d 29) with 250 μg Brefeldin A and were euthanized 4 h later. Processing of tumors and staining 
with antibodies for CD45.2, CD8 (surface), and IFN- (intracellular) was performed in the presence of 10 μg/mL Brefeldin A. Each symbol represents values from indi-
vidual mice at the end of the experiment.
cross-presentation at the relevant anatomic location. This is not 
trivial, as systemic activation of DCs may not be without risk as 
systemic side effects such as the release of cytokines or 
autoimmunity may ensue (31, 32).
We found that 12D7 improved the efficacy of chemotherapy in 
a preclinical mouse model of transplanted, syngeneic NY-ESO-
1-expressing tumors, thus supporting our concept. Further 
support comes from the fact that more CD8+ T cells infiltrate 
the tumor and that those cells have increased effector function. 
By itself, however, 12D7 had no therapeutic effect, suggesting 
that the amount of released tumor antigen is limiting without 
deliberate destruction of the tumor. Our in vivo experiments 
require the binding of human IgG to mouse Fc receptors 
(FcR), which was previously described (33, 34). Improved 
efficacy of chemotherapy by the use of tumor-associated 
antigen-specific antibodies will presumably work for 
chemotherapies especially, which are not immunosuppressive 
or—even more important—promote immunogenic cell death 
(35).
We propose the concept of antibody-facilitated T cell 
induction in cancer (AFTIC) as a novel type of immunotherapy. 
AFTIC is based on the application of mAbs against tumor-
associated antigens, including CT antigens, plus a treatment that 
promotes the local release of those antigens, such as chemo- or 
radiotherapy. The locally released antigens and the mAb form 
immune complexes, which facilitate the uptake and subsequent 
presentation of antigen-derived peptides by tumor-associated 
DCs. As the uptake of immune complexes induces concomitant 
maturation of DCs, AFTIC supports boosting as well as de novo
activation of tumor-specific CD8+ T cells. Furthermore, 
administration of antibodies against a particular tumor-
associated antigen may promote the presentation of the same 
antigen when administrated as a cancer vaccine, thereby 
improving the efficacy of immunotherapy. Alternatively, better 
antigen presentation of immune complexes and concomitant 
DC maturation may support the activity of adoptively 
transferred T cells provided they have the same antigen 
specificity as the therapeutic antibodies.
Abbreviations
CT, Cancer/Testis; DC, dendritic cell; mAb, monoclonal anti-
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Materials and methods
Patient material
Serum and peripheral blood was collected from cancer 
patients. All patients were admitted at the University Hospital 
Zürich and provided written informed consent in accordance 
with the Declaration of Helsinki. The local ethics committee 
approved the study.
Memory B cell culture
PBMC were incubated with anti-CD22 coupled to magnetic 
beads (Miltenyi Biotec), PE-conjugated anti-IgD, and APC-
conjugated antibodies to IgM, CD3, CD8, and CD56 (Becton 
Dickinson). B cells were isolated by positive selection of CD22+ 
cells using a midi-MACS device and LS columns (Miltenyi 
Biotec), followed by sorting PE-APC- cells using a MoFlo cell 
sorter (Beckman Coulter). CD22+ IgD- IgM- memory B cells 
were incubated with 10% EBV-containing supernatant from 
B95-8 cells (from European Collection of Cell Cultures, 
ECACC) in the presence of 2.5 μg/mL CpG 2006 at 37°C for 4 h. 
Cells were seeded in 96-well U-bottom plates at 10 cells per well 
plus 3 x 104 irradiated allogeneic PBMCs in RPMI 1640 medium 
supplemented with 10% human serum, antibiotics, 10% 
supernatant from B95-8 cells, and 2.5 μg/mL CpG 2006. 
Supernatants were tested for NY-ESO-1-specific antibodies after 
2 weeks by ELISA.
Single cell-RT-PCR
B cell cultures were harvested and single cells were deposited 
into a 96-well PCR plate (Applied Biosystems) using a MoFlo 
XDP cell sorter (Beckman Coulter). RT-PCR was performed 
using random hexamer primers for cDNA synthesis and specific 
primers to amplify the immunoglobulin variable and constant 
regions. Immunoglobulin heavy and light chain variable regions 
were amplified using a nested PCR approach as described (36). 
Primer-encoded amino acid sequences and J-C regions of the 
antibodies were corrected to represent the authentic amino acid 
sequence as it occurred in the patient in a subsequent step prior 
to antibody production.
Antibody production and purification
293-T human embryonic kidney cells were transfected with 25 
kDa branched polyethylenimine (PEI, Polysciences, 
Warrington, PA) plus DNA plasmids (heavy and light chain in 
equal ratios) in a 1.3:1 ratio and were incubated for 15 min at 
room temperature. Following transfection, the cells were 
cultured in serum free Opti-MEM I + GlutaMAX-I (Invitrogen) 
supplemented with 10 U penicillin-streptomycin (Lonza, 
Switzerland). After 72 h supernatants were collected and IgG 
was purified on a protein A column (GE Healthcare, Sweden) 
using FPLC (GE Healthcare, Sweden).
Biacore analysis
Antibody binding kinetics with NY-ESO-1 proteins derived 
from E. coli (LICR New York Branch) and HEK293 cells 
(OriGene Technologies, Inc.) were determined by Biacore 
technology (model Biacore 2000; Biacore AB) using CM5 sensor 
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chips, EDC-NHS conjugation, and BIAevaluation software. 
Technical details have been described previously (37).
ELISA
• Protein or peptide ELISA
96-well half-area microtiter plates (Costar, USA) were coated 
with 30 μL/well of 1 μg/mL recombinant NY-ESO-1 protein, or 
10 μg/mL 20-mer peptides spanning the entire NY-ESO-1 
protein (Peptides & Elephants, Germany) diluted in PBS 
overnight at 4°C. After coating, plates were washed with PBS + 
0.05% Tween-20 (PBS-T) and blocked for 1 h at room 
temperature with 2% BSA/PBS (Sigma). B cell-conditioned 
medium, patient serum, or recombinant antibody was 
incubated for 2 h at room temperature (RT) at indicated 
concentrations or dilutions in PBS. Plates were washed with 
PBS-T and incubated for 1 h at RT with HRPO-conjugated goat-
anti-human Fc antibody (Jackson ImmunoResearch), diluted 
1:4000 in 0.5% BSA/PBS, followed by measurement of the 
HRPO activity using a TMB substrate solution (Sigma, Buchs, 
Switzerland). The mouse IgG1 monoclonal anti-NY-ESO-1 
antibody E978 (38) and HRPO-conjugated goat-anti-mouse Fc
antibody (Jackson ImmunoResearch) at 1:4000 dilution in 0.5% 
BSA/PBS served as positive control.
• Cellular ELISA
4 x 104 SK-MEL-37 cells were seeded in a 96-well flat bottom 
plate and cultured under standard conditions overnight. Cells 
were fixed in ice-cold ethanol/acetone mix (1:1) for 15 min on 
ice. After two wash steps with PBS, cells were blocked and 
permeabilized with 100 μL of PBS + 0.5% BSA + 0.5% Triton X 
100 for 2 h at 4°C. B cell-conditioned medium or recombinant 
antibody was incubated at indicated concentrations for 2 h at 
4°C. Bound antibodies were detected after 1 h incubation at 4°C 
with HRPO-labeled goat anti-human Fc secondary antibody 
(Jackson ImmunoResearch).
Immunoprecipitation
SK-MEL-37 tumor cells were lysed with Triton X 100/
Glycerol-based lysis buffer for 15 min at 4°C. Cell debris was 
separated by centrifugation at maximum speed in a table 
centrifuge and protein concentration of the supernatant 
analyzed by standard Bradford assay. 300 ng of antibody was 
used to precipitate NY-ESO-1 from 250 μg of SK-MEL-37 cell 
lysate in a 16 h incubation at 4°C. The immune complex was 
isolated by adding magnetic Protein G beads (New England 
Biolabs, Ipswich, MA) for 1 h at 4°C under constant agitation. 
Beads were washed, resuspended in NuPAGE LDS sample buffer 
(Invitrogen) and boiled prior to Gradient SDS Polyacrylamide 
Gel Electrophoresis (NuPAGE 4-12% Bis-Tris Gel, Invitrogen). 
NY-ESO-1 protein was detected by Western blot using murine 
antibody E978 (38). 
In vitro cross-presentation assay
Human, HLA-A*0201/NY-ESO-1157-165 specific CD8+ T cells 
were cloned as previously described (39). To generate DCs, 
CD14+ cells were MACS-purified according to the 
manufacturer’s instructions (Miltenyi Biotech) from PBMC 
from HLA-A*0201+ healthy donors and cultured at 106 cells/mL 
in serum-free CellGro DC media (CellGenix), supplemented 
with 800 U/mL GM-CSF and 500 U/mL IL-4 (R&D Systems) to 
generate DCs. Medium was exchanged the following day and 
DCs were harvested on d 4 of culture and resuspended at 106/
mL in Opti-MEM (Gibco). Immune complexes were generated 
by incubating 20 μg recombinant NY-ESO-1 with 200 μg 12D7 
in a total volume of 500 μL Opti-MEM (Gibco) for 30 min at 
37°C. Human IgG1 (Sigma Aldrich), 12D7 alone, or NY-ESO-1 
alone were used as controls. Alternatively, 200 μg 12D7 was 
incubated with a lysate of an equivalent of 107 NY-ESO-1+ SK-
MEL-37 cells in 500 μL Opti-MEM. DCs (5x105 in 0.5 mL Opti-
MEM) were added to the immune complexes and controls. The 
mixture was incubated at 37°C for 3 h. DCs were then 
centrifuged and resuspended in CellGro DC media at 106/mL. 
Hundred μL (105 DCs) were cultured in 96-well flatbottom 
plates at 37°C in the presence or absence of maturation cocktail 
(1 μg/mL soluble CD40L (sCD40L) trimer (PeproTech) plus 
TNF-α (25 ng/mL; R&D Systems)). After 36 h, approximately 6 
x 105 HLA-A*0201/NY-ESO-1157-165 specific CD8+ T cells in 100 
μL RPMI + 10% human serum + antibiotics + 20 μg/mL 
Brefeldin A (Sigma Chemicals) were added to the different DC-
cultures. After 4 h, cultures were harvested in FACS buffer (PBS 
+ 2% FCS + 2 mM EDTA + 0.05% NaN3) and surface stained 
with anti-CD8 followed by intracellular staining for IFN- as 
previously described (39). CD8+ T cells plus unloaded DCs 
served as negative control, and CD8+ T cells plus DCs with 10-6
M of NY-ESO-1157-165 (SLLMWITQC, Thermo Fisher Scientific) 
served as positive control. All cultures were performed at least in 
duplicates.
Mice and cell lines
BALB/c mice were originally obtained from Jackson 
Laboratories and were bred and kept under specific pathogen-
free conditions in the Institute of Laboratory Animal Sciences 
(University of Zürich). Age- and sex-matched mice of 9-12 
weeks old were used for all experiments. Mice were housed 
under specific pathogen-free conditions at University Hospital 
Zürich. All experiments were performed in agreement with the 
federal and cantonal laws on animal protection.
The colon carcinoma cell line CT26 was transfected to stably 
express intracellular NY-ESO-1 (40) and was cultured in RPMI 
+ 10% FCS + antibiotics + 10 μg/mL puromycin under standard 
tissue culture conditions. CT26/NY-ESO-1 and the human 
melanoma cell line SK-MEL-37 were cultured in RPMI + 10% 
FCS + antibiotics under standard tissue culture conditions. 293-
T cells were cultured in DMEM (Lonza, Switzerland) 
supplemented with 10% FCS (Linaris) and 10 U penicillin-
streptomycin (Lonza, Switzerland) under standard tissue culture 
conditions. 
Treatment of mice
Mice were injected s.c. into the right flank with 106 CT26/NY-
ESO-1+ cells in 100 μL RPMI. The tumor surface was measured 
at least twice a week with a calliper. Treatment was started (d 0) 
when tumors reached a size of approximately 25 mm2. 5-
Fluorouracil (5-FU, TEVA Pharma, Aesch, Switzerland) was 
diluted in saline and were given i.p. on d 0 and d 7 at 75 mg/kg, 
respectively. 12D7 (100 μg in 100 μL PBS) was given i.p. on d 2 
and d 9. All animal experiments were performed in accordance 
with the Swiss federal and cantonal law on animal protection.
Flow cytometry
At the end of the experiment (1 week after the last injection of 
12D7), mice were injected i.p. with 250 μg Brefeldin A and were 
euthanized 4 h later. Subsequent processing and staining was 
performed in the presence of 10 μg/mL Brefeldin A (25). 
Tumors were cut into small pieces and subsequently digested 
with 1.5 mg/mL collagenase + 100 μg/mL DNase for 1 h at 37°C 
followed by filtration through a 50 μm cell strainer. Single cell 
suspensions were surface stained in FACS buffer (FB, PBS + 2% 
FCS + 0.03% NaN3 + 20 mM EDTA) with anti-CD45.2 pacific 
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blue and anti-CD8bPE. For intracellular staining to detect IFN-
, cells were permeabilized with permeabilization buffer (PB, FB 
+ 0.1% saponin) and stained intracellularly with anti-IFN-
APC. All antibodies were obtained from BioLegend, San Diego, 
CA, USA. Samples were measured with a CyAn ADP9 
(Beckman Coulter, Brea, CA, USA) and analyzed using FlowJo 
Analysis Software (Tree Star Inc., Ashland, OR, USA).
Statistical analysis
Statistics were done using an unpaired Student two-tailed t-
test. Error bars represent SD. p values less than 0.05 were 
considered significant.
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